Genmab Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Genmab's estimated annual revenue is currently $98.4M per year.
- Genmab received $10.0M in venture funding in October 2014.
- Genmab's estimated revenue per employee is $155,000
- Genmab's total funding is $134M.
- Genmab has 635 Employees.
- Genmab grew their employee count by 37% last year.
- Genmab currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
What Is Genmab?
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimerkeywords:N/A
Number of Employees
Employee Growth %
|Annette Ervin-Haynes||Vice President||Email Available|
|Carl Sharo||Associate Director of Facilities|
|Jan van de Winkel||CEO/President||Email Available|
|David Eatwell||Executive Vice President & Chief Financial Officer||Email Available|
|Birgitte Stephensen||SVP Legal/IPR||Email Available|
|Anthony Pagano||Svp Global Finance & Corporate Development||Email Available|
|Rachel Gravesen||Senior Vice President, Investor Relations and Communications|
|Dena Demarco||Sr. Director, Clinical Research Scientist|
|Maryanne Mccarthy||Sr. Director Alliance Management|
|Martine van Vugt||SVP Strategic Initiatives||Email Available|
Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned ...
Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that ...
Company Announcement. Copenhagen, Denmark; August 20, 2019 – Genmab A/S (Nasdaq:GMAB) will increase its share capital by 21,811 ...
|2014-10-27||$10.0M||Undisclosed||Janssen Biotech Inc||Article|
Genmab Executive Hires
|2017-02-10||Judith Klimovsky||Chief Development Officer||Article|